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TMEM97 and PGRMC1 do not mediate
sigma-2 ligand-induced cell death
Chenbo Zeng1, Chi-Chang Weng1, Mark E. SchneiderJr.1, Laura Puentes1, Aladdin Riad1, Kuiying Xu1,
Mehran Makvandi1, Linda Jin2, William G. Hawkins2 and Robert H. Mach1
Abstract
Sigma-2 receptors have been implicated in both tumor proliferation and neurodegenerative diseases. Recently the
sigma-2 receptor was identiﬁed as transmembrane protein 97 (TMEM97). Progesterone receptor membrane
component 1 (PGRMC1) was also recently reported to form a complex with TMEM97 and the low density lipoprotein
(LDL) receptor, and this trimeric complex is responsible for the rapid internalization of LDL. Sigma-2 receptor ligands
with various structures have been shown to induce cell death in cancer cells. In the current study, we examined the
role of TMEM97 and PGRMC1 in mediating sigma-2 ligand-induced cell death. Cell viability and caspase-3 assays were
performed in control, TMEM97 knockout (KO), PGRMC1 KO, and TMEM97/PGRMC1 double KO cell lines treated with
several sigma-2 ligands. The data showed that knockout of TMEM97, PGRMC1, or both did not affect the
concentrations of sigma-2 ligands that induced 50% of cell death (EC50), suggesting that cytotoxic effects of these
compounds are not mediated by TMEM97 or PGRMC1. Sigma-1 receptor ligands, (+)-pentazocine and NE-100, did not
block sigma-2 ligand cytotoxicity, suggesting that sigma-1 receptor was not responsible for sigma-2 ligand
cytotoxicity. We also examined whether the alternative, residual binding site (RBS) of 1,3-Di-o-tolylguanidine (DTG)
could be responsible for sigma-2 ligand cytotoxicity. Our data showed that the binding afﬁnities (Ki) of sigma-2 ligands
on the DTG RBS did not correlate with the cytotoxicity potency (EC50) of these ligands, suggesting that the DTG RBS
was not fully responsible for sigma-2 ligand cytotoxicity. In addition, we showed that knocking out TMEM97, PGRMC1,
or both reduced the initial internalization rate of a sigma-2 ﬂuorescent ligand, SW120. However, concentrations of
internalized SW120 became identical later in the control and knockout cells. These data suggest that the initial
internalization process of sigma-2 ligands does not appear to mediate the cell-killing effect of sigma-2 ligands. In
summary, we have provided evidence that sigma-2 receptor/TMEM97 and PGRMC1 do not mediate sigma-2 ligand
cytotoxicity. Our work will facilitate elucidating mechanisms of sigma-2 ligand cytotoxicity.
Introduction
The sigma receptor was originally deﬁned pharmaco-
logically1. The sigma receptor was once thought to be a
subset of the opioid receptor2, but was subsequently
revealed to be a distinct class of receptors1. There are two
subtypes of sigma receptors, sigma-1 and sigma-2
receptors. The molecular weight of sigma-1 and sigma-2
receptors was previously reported to be 25 and 18–21.5
kD, respectively3. The sigma-2 receptor has been shown
to be expressed in higher density in proliferating versus
quiescent tumor cells4,5. Sigma-2 ligands have been
developed as molecular probes for imaging solid tumors
and also as potential therapeutic agents for treating can-
cer6. A sigma-2 receptor ligand has also shown promise as
a novel approach for treating Alzheimer’s disease (AD)7,8.
Recently, transmembrane protein 97 (TMEM97), a
protein implicated in cancer and cholesterol homeostasis,
was identiﬁed as the sigma-2 receptor9. TMEM97 has a
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role in cholesterol and lipid metabolism10–12, and it was
reported that TMEM97 and cholesterol biosynthesis
genes in normal ovarian epithelial cells were coordinately
upregulated by progesterone treatment10. In another
report, TMEM97 was identiﬁed as a regulator of cellular
cholesterol homeostasis in targeted RNAi screening11.
TMEM97 knockdown reduced cellular cholesterol levels
as well as the rate of internalization of low density lipo-
protein (LDL) uptake by the LDL receptor (LDLR). Fur-
thermore, cell cultures growing under sterol-depleted
conditions results in an upregulation of TMEM97 mRNA
levels11. These data indicated that TMEM97 has a key role
in the regulation of cholesterol homeostasis.
Previously, our group proposed that the binding site for
the sigma-2 receptor resided in a protein complex con-
taining the progesterone receptor membrane component
1 (PGRMC1)13. Subsequent studies challenged the validity
of our results14,15, and the recent identiﬁcation of the
TMEM97 as the gene for the sigma-2 receptor seemed to
substantiate these reports9. However, our group recently
reported that TMEM97 formed a complex with PGRMC1
and LDLR, and this trimeric complex was responsible for
the rapid internalization of LDL in HeLa cells16. These
data demonstrated that PGRMC1 associates with
TMEM97 physically and functionally, and corroborates
our previous report that the sigma-2 receptor represents a
binding site in the PGRMC1 protein complex.
TMEM97 (initially called MAC30) was ﬁrst reported as
a differentially expressed gene in meningioma17.
TMEM97 was decreased in meningioma compared to
normal leptomeningeal tissues. Subsequent studies
showed that TMEM97 was overexpressed in gastric can-
cer18, colorectal cancer19, breast cancer20, glioma21, and
ovarian cancer22 cells. Overexpression of TMEM97 was
positively correlated with tumor stage, metastasis, and
shorter survival time of patients with various cancers19,22.
The differential expression of TMEM97 in cancer cells
suggest that this protein may have a role in tumor
development, growth, and proliferation.
The sigma-2 receptor is a potential target for cancer
therapeutics6,23. Sigma-2 ligands have been shown to
induce cytotoxicity in cancer cells as a single agent, a drug
delivery agent24,25 and a sensitizer to other anticancer
drugs in cell culture and in animal models. Sigma-2
ligands trigger cell death by inducing lysosome dysfunc-
tion, ROS production, caspase-independent, and caspase-
dependent events26–31. However, it is not known how
sigma-2 ligands interact with sigma-2 receptors and
induce subsequent cell death. Sigma-2 ligands have
nanomolar binding afﬁnities to sigma-2 receptors but
require micromolar range of concentrations to exhibit
cell-killing effects6. The factors responsible for the large
difference between sigma-2 receptor afﬁnity and potency
in the cell-kill assays are currently unknown.
In the current study, we studied whether TMEM97 or
PGRMC1 mediated sigma-2 ligand-induced cell death.
We show that CRISPR/Cas9 gene editing of TMEM97
and PGRMC1 did not affect the cytotoxicity of a panel of
structurally diverse sigma-2 ligands. We also examined
whether the alternative residual binding site of DTG, a
gold standard sigma-2 ligand, in TMEM97 knockout (KO)
and TMEM97/PGRMC1 double KO cells could be
responsible for sigma-2 ligand cytotoxicity. Our data
showed that this residual binding site of DTG does not
appear to be responsible for the cytotoxicity of sigma-2
ligands, and raises a question regarding the mechanism of
action of these ligands as anticancer drugs.
Results
Knockout of TMEM97, PGRMC1, or both proteins did not
affect EC50 values of sigma-2 ligands
Sigma-2 ligands were previously reported as potential
therapeutic drugs in various cancer cells in cell culture
and in animal models. In order to study whether the
cytotoxicity of sigma-2 ligands was mediated by TMEM97
or PGRMC1, we compared cell-killing potency of sigma-2
ligands in control, TMEM97 KO, PGRMC1 KO, and
double KO HeLa cells. These cell lines were previously
created in our laboratory using CRISPR/Cas9 technology
and western blot data demonstrated that TMEM97 or/
and PGRMC1 proteins were completely removed in the
knockout cell lines16. Three sigma-2 agonists SW43, sir-
amesine and PB28, and three sigma-2 antagonists RHM-
4, RHM-1, and ISO-1 were studied in this study. The
diverse chemical structures of these ligands and their
binding afﬁnities obtained by the competition assay for
sigma-1 and sigma-2 receptors were shown in Fig. 1 and
Table 1. The control and knockout cells were incubated
with sigma-2 ligands at increasing concentrations for 24 h
and cell viability assay was performed. Dose–response
curves were generated as shown in Fig. 2a. EC50 values of
sigma-2 ligands in each cell line determined from the
dose–response curves are shown in Fig. 2b and Table 2.
The data showed that knockout of TMEM97, PGRMC1,
or both proteins did not affect EC50 values of sigma-2
agonists. Similarly, sigma-2 antagonists exhibited little
cytotoxicity (EC50 > 200 µM) in all the four cell lines as
expected (Fig. 2a and Fig. S2A). These data suggest that
sigma-2 ligand-induced cytotoxicity is not mediated by
TMEM97, PGRMC1 or both of the proteins.
The aforementioned TMEM97 KO cell line was gen-
erated by CRISPR/Cas9 technology using guide RNA1.
We tested whether TMEM97 KO cell lines generated
using different guide RNAs resulted in the same results.
We performed cell viability assays on TMEM97 KO cell
lines generated using guide RNA2 (TMEM97 KO-g2) and
guide RNA3 (TMEM97 KO-g3). The data showed that the
sigma-2 agonists kill cells with similar EC50 values in the
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control, TMEM97 KO-g2 and TMEM97 KO-g3 cells
(Fig. S2B). Moreover, we performed cell viability assay on
another set of single protein knockout cell lines, i.e., three
clones of PGRMC1 KO cells and three clones of corre-
sponding control cells. The data showed that knockout of
PGRMC1 did not affect EC50 values of the sigma-2 ago-
nists (Fig. S2C). All cell lines used in the study were
subject to western blot analysis to conﬁrm that TMEM97,
PGRMC1, or both proteins were stably knocked out








































































Fig. 1 Chemical structures and assessment of binding afﬁnities for sigma-1 and sigma-2 receptors. a Chemical structures of sigma-2 ligands
used in the current study. b Competition curves of [3H](+)-pentazocine binding for sigma-1 receptors on guinea pig brain membranes and [3H]DTG
binding for sigma-2 receptors on rat liver membranes in the presence of increasing concentrations of non-radioactive sigma-2 ligands
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S2C). These data further indicated that TMEM97,
PGRMC1, or both did not appear to mediate sigma-2
ligand-induced cell death.
In order to study whether TMEM97, PGRMC1, or both
mediate caspase-3 activation in sigma-2 ligand-induced
cell death, control, TMEM97 KO, PGRMC1 KO and
double KO cells were treated with siramesine and SW43
for 24 h and then a caspase-3/7 assay was performed.
Dose responsive curves were generated and EC50 values
were determined (Fig. 3). The data showed that the EC50
values for control, TMEM97 KO and PGRMC1 KO cell
lines were identical. The EC50 values generated by cas-
pase-3/7 assays were comparable to the EC50 values
determined by the cell viability assays (data not
shown). These data suggest that TMEM97 or PGRMC1
did not mediate sigma-2 ligand-induced caspase-3
activation.
Sigma-1 receptor ligands did not block sigma-2 ligand-
induced cytotoxicity
The sigma-2 ligands used in the current study are also
expected to bind to sigma-1 receptors in the concentra-
tion range used in the cell viability assay (Fig. 1). In order
to study whether sigma-2 ligand-induced cytotoxicity is
mediated by sigma-1 receptors, we used a sigma-1 ago-
nist, (+)-pentazocine, or sigma-1 antagonist, NE-100, to
block the sigma-1 binding site and then examined sigma-2
ligand-induced cytotoxicity. We ﬁrst showed that
(+)-pentazocine or NE-100 by itself did not exhibit
cytotoxicity (EC50 > 200 µM) in control, TMEM97 KO,
PGRMC1 KO, and double KO cells (Fig. 4a). We pre-
incubated cells with vehicle (cell culture media), 30 µM
(+)-pentazocine, or 30 µM NE-100 for 1 h, then treated
cells with sigma-2 agonists in the absence or presence of
(+)-pentazocine or NE-100 for 24 h. The cell viability
data showed that neither (+)-pentazocine nor NE-100
blocked sigma-2 ligand-induced cytotoxicity (Fig. 4b, c),
suggesting that sigma-1 receptors did not mediate the
observed sigma-2 ligand-induced cytotoxicity.
The DTG residual binding site did not appear to mediate
cytotoxicity of sigma-2 ligands
Our laboratory recently reported that [125I]RHM-4
binding was completely eliminated after TMEM97 was
knocked out, suggesting that [125I]RHM-4 had one spe-
ciﬁc binding site, the sigma-2 receptor/TMEM97. We also
observed that [3H]DTG binding was signiﬁcantly but not
completely reduced after TMEM97 was knocked out,
suggesting that [3H]DTG bound to TMEM97 as well as
one or more unidentiﬁed proteins. We called the
remaining DTG binding site “the DTG residual binding
site (RBS)”. We then explored whether the DTG RBS
mediates the cytotoxicity of sigma-2 ligands used in this
study. We determined the inhibition constant (Ki) values
of sigma-2 ligands for the DTG RBS using a competition
assay (Fig. 5a-c). The data showed that the Ki values for
SW43 was 33,520 or 8615 nM on TMEM97 KO or double
KO cell membranes, respectively, suggesting that SW43
had little binding afﬁnity for the DTG RBS, thus the
cytotoxicity of SW43 on TMEM97 KO cells (EC50= 30.4
μM) or double KO cells (EC50= 32.8 μM) did not appear
to be mediated by the DTG RBS. Moreover, we compared
the Ki values and EC50 values for siramesine and PB28. As
shown in Fig. 5c, the Ki values of siramesine were 115.2 or
49.7 nM on TMEM97 KO or double KO cell membranes,
respectively, and the Ki values for PB28 were 8.7 or 5.2
nM on TMEM97 KO or double KO cell membranes,
respectively. As shown in Table 2, the EC50 values of
siramesine were 10.3 or 10 μM for TMEM97 KO or
double KO cells, respectively, and the EC50 values of
PB28 were 59.8 or 57.4 μM for TMEM97 KO or double
KO cells, respectively. These data indicated that the Ki
values of siramesine and PB28 negatively correlated with
their EC50 values. These data do not exclude the possi-
bility that the DTG RBS mediates the cytotoxicity of sir-
amesine and PB28. However, the data showed that the
DTG RBS was not fully responsible for siramesine and
PB28 cytotoxicity.
Knockout of TMEM97, PGRMC1, or both proteins reduced
the initial internalization rate of the sigma-2 ﬂuorescent
ligand, SW120
In order to determine whether TMEM97, PGRMC1,
or both proteins together are responsible for inter-
nalization of sigma-2 ligands, the internalization rate of
a sigma-2 ﬂuorescent ligand, SW120, was measured.
Control, TMEM97 KO, PGRMC1 KO, or double KO
cells were incubated with 100 nM SW120 and time-
lapse images were immediately taken after addition of
SW120 at 25-sec intervals for 18 min using an inverted
confocal microscope (Fig. 6a and Fig. S3). Compared to
Table 1 The binding afﬁnities of sigma-2 ligands for
sigma-1 and sigma-2 receptors
Ki for sigma-1 receptors
(nM)
mean ± SD
Ki for sigma-2 receptors
(nM)
mean ± SD
Siramesine 3.0 ± 0.5 1.6 ± 0.1
SW43 277.9 ± 65.0 12.9 ± 2.3
PB28 1.1 ± 0.1 1.1 ± 0.3
RHM-4 3606.0 ± 533.3 2.4 ± 0.2
RHM-1 1925.3 ± 625.4 3.8 ± 0.7
ISO-1 23.9 ± 1.9 2.0 ± 0.6
SW120 1942.3 ± 262.3 1.0 ± 0.3
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the control cells, TMEM97 KO, PGRMC1 KO and
double KO cells exhibited reduced internalization rates
of SW120. The data suggested that SW120 inter-
nalization was in part mediated by TMEM97 and/or
PGRMC1. On the other hand, the observation that
SW120 could still enter TMEM97 KO, PGRMC1 KO,
and double KO cells suggested that SW120 uptake
could also be mediated in a TMEM97-independent and/
or PGRMC1-independent manner. We also examined
SW120 uptake at longer time points, i.e., 15, 30, 60, 90,
and 120 min. As shown in Fig. 6b, although SW120
uptake signals at 15 and 30 min time points were lower
in the knockout cells than the control cells, SW120
uptake signals at 60, 90, and 120 min were essentially the
same for all the cell lines. These results are consistent
with our data that sigma-2 ligands did not show any
Double KOPGRMC1 KO
TMEM97 KO
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Fig. 2 Cytotoxicity of sigma-2 ligands determined by cell viability assay. Control, TMEM97 KO, PGRMC1 KO, or double KO cells were treated with
increasing concentrations of sigma-2 ligands for 24 h. The cell viability was then determined by CellTiter Glo® chemiluminescent assay. a
Representative dose–response curves of cell viability for the control and knockout cell lines. b EC50 values of sigma-2 ligands were represented as bar
graphs. EC50 values were reported as mean ± SD from at least two independent experiments performed in triplicates. No signiﬁcant difference
existed for EC50 values of sigma-2 ligands in TMEM97 KO, PGRMC1 KO, or double KO cells vs control cells by 2-way Anova analysis. c Representative
western blot analysis for TMEM97 and PGRMC1 in the control and knockout cell lines used in the current study
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difference in cytotoxicity after 24 h treatment in the
control and knockout cells.
Discussion
In this study, we showed that the knockout of
TMEM97, PGRMC1, or both proteins in HeLa cells did
not affect the EC50 values of sigma-2 ligands, suggesting
that sigma-2 ligand-induced cytotoxicity is not mediated
by TMEM97, PGRMC1, or the combination of both
proteins. Furthermore, we determined the Ki values of
sigma-2 ligands for the DTG RBS and the data suggest
that the DTG RBS is not, at least, fully responsible for
sigma-2 ligand-induced cytotoxicity.
In order to study whether the sigma-2 receptor med-
iates sigma-2 ligand-induced cell death, we treated con-
trol, TMEM97 KO, PGRMC1 KO, or double KO cells
with various sigma-2 ligands developed by our laboratory
as well as by other groups. Our data showed that sigma-2
ligands exhibited cytotoxicity with essentially the same
potency in the control and the knockout cells (Figs. 2 and
3, and Fig. S2). The data suggest that the cell-killing
effects of sigma-2 ligands were not mediated by
TMEM97, PGRMC1, or the combination of both proteins.
Since the sigma-2 ligands also possess nanomolar to
micromolar binding afﬁnities to sigma-1 receptors, we
examined whether sigma-2 ligand-induced cytotoxicity
was mediated by sigma-1 receptors. Our data showed that
a sigma-1 agonist, pentazocine, and an antagonist, NE-
100, did not block sigma-2 ligand-induced cytotoxicity
(Fig. 4a-c). Also, the EC50 values of sigma-2 ligands did
not appear to correlate with their Ki values for sigma-1
receptors (Tables 1 and 2). These results suggest that
sigma-2 ligand-induced cytotoxicity was not mediated by
sigma-1 receptors. Future studies using sigma-1 receptor
knockout cell lines might help further delineate this
observation.
Our group recently found that [3H]DTG binding was
signiﬁcantly reduced, but not completely abolished, in the
TMEM97 KO and double KO cells. This observation
suggests that there exists an additional DTG binding site,
a site we have termed the “DTG residual binding site
(RBS)”. The Kd for the [
3H]DTG RBS are 302.0 and 402.6
nM for TMEM97 KO and double KO cell membranes16,
Table 2 EC50 values of sigma-2 ligands in control,









Siramesine 12.1 ± 1.7 10.3 ± 1.49 10.7 ± 0.7 10.0 ± 1.3
SW43 33.7 ± 8.6 30.4 ± 3.4 33.2 ± 1.6 32.8 ± 3.8
PB28 58.2 ± 5.9 59.8 ± 10.7 59.4 ± 8.0 57.4 ± 6.9
RHM-4 >200 >200 >200 >200
RHM-1 >200 >200 >200 >200














































































Fig. 3 Caspase-3 activities induced by sigma-2 ligands. Control,
TMEM97 KO, PGRMC1 KO, or double KO cells were treated with
increasing concentrations of sigma-2 ligands for 24 h. Caspase-3
activation was then determined by Caspase-Glo 3/7 Assay. a, b
Representative dose–response curves of caspase-3 activity for
siramesine (a) and SW43 (b). c EC50 values of caspase-3 activation of
sigma-2 ligands were represented as bar graphs. EC50 values were
reported as mean ± SD in at least two independent experiments
performed in triplicates. No signiﬁcant difference existed for EC50
values of sigma-2 ligands in TMEM97 KO, PGRMC1 KO, or double KO
cells vs the control cells by two-way Anova analysis with one
exception, i.e., there was a signiﬁcant difference (asterisk) of EC50 of
siramesine in double KO cells vs control cells
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Fig. 4 Sigma-1 ligands did not block sigma-2 ligand cytotoxicity. a A sigma-1 agonist, (+)-pentazocine, and a sigma-1 antagonist, NE-100, did
not exhibit cytotoxicity in the control and knockout cells. b Representative dose–response curves of cell viability for siramesine and SW43 in the
absence or presence of 30 μM (+)-pentazocine or NE-100. c EC50 values of sigma-2 ligands were represented as bar graphs. EC50 values were
reported as mean ± SD in at least two independent experiments performed in triplicates. No signiﬁcant difference existed for EC50 values of sigma-2
ligands plus (+)-pentazocine or NE-100 vs sigma-2 ligands only in all the four cell lines by two-way Anova analysis
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Fig. 5 Assessment of binding afﬁnities of sigma-2 ligands for the DTG RBS. a, b Competition curves of [3H]DTG (45 nM) binding on TMEM97 KO
(a) and double KO (b) cell membranes in the presence of increasing concentrations of non-radioactive sigma-2 ligands. 500 nM of (+)-pentazocine
was used to mask the sigma-1 receptor binding site. The non-speciﬁc binding was determined in the presence of 60 μM cold DTG. c The binding
afﬁnities (Ki) of sigma-2 ligands for the DTG RBS. Ki values were reported as mean ± SD in three independent experiments performed in duplicates
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Fig. 6 Internalization kinetics of SW120. a Control, TMEM97 KO, PGRMC1 KO, or double KO cells were incubated with 100 nM SW120 at room
temperature and time-lapse images were immediately taken after addition of SW120 at 25-s intervals for 18 min using an inverted confocal
microscope. Fluorescence intensity of SW120 in the cells was quantiﬁed and presented as function of internalization time. b Cells were incubated
with 100 nM SW120 for 15, 30, 60, 90, and 120min at room temperature. Confocal images were taken at indicated time points. Fluorescence intensity
of SW120 in the cells was quantiﬁed and presented as function of internalization time. The ﬂuorescence intensities were reported as mean ± SEM in
three independent experiments
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respectively, indicating that [3H]DTG binding afﬁnity to
this residual site is relatively low when compared to its
binding afﬁnity for TMEM97 proteins in the control cell
membranes (Kd= 14.8 nM). The Bmax for the DTG RBS
are 1218 and 1374 fmole/mg for TMEM97 KO and
double KO cell membranes, respectively, indicating that
the maximal binding capacity is moderate when com-
pared to the Bmax (2664 fmole/mg) for control cell
membranes. The DTG RBS is obviously not TMEM97 or
PGRMC1 because this residual site exists in the double
knockout cells. The DTG RBS is not traditional sigma-1
receptor binding site since 500 nM (+)-pentazocine could
not block [3H]DTG binding to this residual site. We also
examined whether the DTG RBS is responsible for sigma-
2 ligand-induced cytotoxicity. We performed the com-
petition assays and determined Ki values of sigma-2
ligands for the DTG RBS (Fig. 5). Our data showed that
SW43 has a low afﬁnity (33,520 or 8615 nM on TMEM97
KO or double KO cell membranes, respectively) for this
residual binding site. Thus it is unlikely that the DTG RBS
mediates SW43 cytotoxicity. Our data also showed that Ki
values for siramesine and PB28 are in the nanomolar
range (i.e., 49.7 and 5.2 nM, respectively, on double KO
cell membranes), suggesting that these two sigma-2
ligands possess good binding afﬁnities to the DTG RBS.
However, their EC50 values were in the micromolar range
(i.e., 10.0 and 57.4 μM for double KO cell membranes) in
the cytotoxicity assay (Table 2). The fact that EC50 values
of siramesine and PB28 are ~200 and ~1000 fold higher,
respectively, than their Ki values again raises the question
whether the DTG RBS mediates the cytotoxicity of sir-
amesine and PB28. Particularly, there is no correlation
between the Ki and EC50 values for siramesine and PB28.
Thus, although these data do not exclude the possibility
that the DTG RBS may mediate the cytotoxicity of certain
sigma-2 ligands, the DTG RBS is not, at least, fully
responsible for sigma-2 ligand-induced cell death, and
other mechanisms may be involved in sigma-2 ligand-
induced cytotoxicity.
It is reported that siramesine, SW43 and PB28 all accu-
mulated in lysosomes and increased lysosomal pH26–28.
Siramesine treatment decreased lysosomal cysteine cathe-
psin activity and decreased lysosomal stability for hypotonic
conditions. Siramesine, SW43 and PB28 also induced
reactive oxygen species (ROS). Therefore, these results
suggest that sigma-2 ligand-induced lysosomal dysfunction
and ROS production are early events that may be respon-
sible for sigma-2 ligand-induced cytotoxicity. Whether
TMEM97, PGRMC1, or the DTG RBS mediate sigma-2
ligand-induced lysosome dysfunction and ROS production
needs to be studied.
Our data showed that knockout of TMEM97, PGRMC1,
or both proteins reduced the internalization rate of a
sigma-2 ligand, SW120 (Fig. 6a). These data are
consistent with our prior report that the internalization of
LDL is mediated by the LDLR/TMEM97/PGRMC1
complex since knocking out either TMEM97, PGRMC1,
or both proteins dramatically reduced the rate of uptake
of radiolabeled LDL. Whether or not the LDLR/
TMEM97/PGRMC1 complex mediates the internalization
of sigma-2 ligands is not known and deserves further
investigation. It is also important to note that although
the concentrations of SW120 in TMEM97 KO and
PGRMC1 KO cells were lower than that in control cells at
early time points of internalization, the cellular con-
centrations of SW120 eventually reach the same plateau
in the knockout and control cells at late time points (>60
min) (Fig. 6b). Thus the ﬁnal concentrations of sigma-2
ligands inside cells under the conditions of the cell via-
bility and caspase-3/7 assays are identical in both the
control and knockout cells, and this could explain why the
initial sigma-2 ligand internalization rate difference did
not affect EC50 values in the knockout cells versus control
cells.
In summary, we have provided evidence that sigma-2
receptor/TMEM97 and PGRMC1 do not mediate the
cytotoxicity of a panel of sigma-2 ligands. Our work with
the TMEM97 and double knockout cells should facilitate




HeLa human cervical cancer cells were from American
Type Culture Collection (ATCC, Manassas, VA). Control,
TMEM97 KO, PGRMC1 KO and TMEM97/PGRMC1
double KO HeLa cell lines were grown in MEM con-
taining 10% fetal bovine serum, 2 mM L-glutamine, 1%
non-essential amino acids, 100 units/ml penicillin, and
100 μg/ml streptomycin. All the cell lines were main-
tained at 37 °C in a humidiﬁed incubator with a 5% CO2/
95% air atmosphere.
Western blot analysis
Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer (Sigma-Aldrich, St. Louis, MO, USA) con-
taining 150mM NaCl, 1.0% IGEPAL® CA-630, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH
8.0 supplemented with protease inhibitor cocktail, and
phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich, St.
Louis, MO, USA). The cells were sonicated brieﬂy, cen-
trifuged at 13,000×g for 20 min at 4 °C, and the super-
natant collected. The protein concentration was
determined using a Bio-Rad Dc protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA). Lysates containing 20
µg of protein were run on a 4–20% acrylamide gel and
transferred to a PVDF membrane using the Trans-Blot
Turbo Transfer System (Bio-Rad Laboratories, Hercules,
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CA, USA). The PVDF membrane was incubated with
Odyssey blocking buffer (Licor Biotechnology, Lincoln,
NE) for 1 h at room temperature, then overnight with a
rabbit anti-TMEM97 antibody (Aviva Systems Biology,
San Diego, CA) at a 1:8000 dilution, or a rabbit anti-
PGRMC1 antibody (Sigma-Aldrich) at a 1:1000 dilution at
4 °C, and ﬁnally with the secondary antibody, IRDye
800CW anti-rabbit IgG (Licor Biotechnology) at a
1:15,000 dilution. The signals were detected and quanti-
ﬁed using the Odyssey® CLx Infrared Imaging System
(Licor Biotechnology).
Cell viability assay
The cytotoxicity of compounds was determined using
the CellTiter Glo® chemiluminescent assay (Promega,
Madison, WI) that measures ATP. Cells were plated in
black wall clear bottom 96-well plates at 5000 cells per
well 24 h before treatment. Each compound was dissolved
in DMSO and serially diluted in culture medium to
acquire the desired concentrations. The ﬁnal concentra-
tion of DMSO in the cell culture medium was no more
than 1.0%. After 24 h treatment with the various com-
pounds, 25 μl of the CellTiter Glo® Solution Reagent was
added to each well. Then plates were immediately read
on a Perkin Elmer Enspire® Multimode Plate Reader.
Luminescence detected for each well was normalized
to the untreated control and data was calculated as per-
cent viability. The EC50, deﬁned as the concentration of
the sigma ligand required to inhibit cell proliferation
by 50% relative to untreated cells, was determined
from the dose–response curves generated using
GraphPad Prism version 6 (GraphPad Software, Inc. La
Jolla, CA).
Caspase-3 assay
HeLa cells were plated in white opaque 96-well plate at
a cell density of 5000 cells per well for 24 h. The cells were
then treated with sigma-2 ligands, SW43, and siramesine
at increasing concentrations for 24 h. Caspase-3/7 activity
was measured by using the Caspase-Glo 3/7 Assay
(Promega).
Sigma-1 and sigma-2 receptor binding assays
The sigma-1 and sigma-2 receptor binding afﬁnities of
sigma-2 ligands were determined using a competition
assay as previously described32,33. For the sigma-1 binding
assay, 100 μg guinea pig brain membrane homogenates
and non-radioactive compounds were incubated with 5
nM [3H](+)-pentazocine in 50mM Tris–HCl, pH 8.0, and
0.1% bovine serum albumin (BSA) for 90min at 37 °C.
The concentrations of each non-radioactive compound
ranged from 0.1 to 10 μM. The non-speciﬁc binding was
determined in the presence of 10 μM haloperidol. For the
sigma-2 binding assay, 60 μg Sprague Dawley rat liver
membrane homogenates and non-radioactive compounds
were incubated with 5 nM [3H]DTG in 50mM Tris–HCl,
pH 8.0, and 0.1% BSA for 60min at 37 °C. The con-
centrations of each non-radioactive compound ranged
from 0.1 nM to 10 μM. 500 nM of (+)-pentazocine was
added to mask the sigma-1 receptor binding site. The
non-speciﬁc binding was determined in the presence 10
μM DTG.
The binding afﬁnities of sigma-2 ligands for the DTG
RBS were determined using a competition assay as
previously described13,33 with minor modiﬁcation. For
cell harvesting, TMEM97 KO or TMEM97/PGRMC1
double KO HeLa cells were scraped from culture dishes
in ice-cold Phosphate-Buffered Saline (PBS) and col-
lected by centrifugation. The cell pellets were immedi-
ately stored at −80 °C until use. For cell membrane
homogenate preparation, the cell pellets were re-
suspended in 10 mL ice-cold PBS, and homogenized
using Wheaton overhead stirrer (120 Vac Overhead
Stirrer, Millville, NJ, USA) at the speed of 2 for 30 sec.
The cell homogenates were then centrifuged for 20 min
at 31,000×g at 4 °C. After centrifugation, the supernatant
was discarded and the pellets were re-suspended in 1 mL
ice-cold PBS and stored at −80 °C freezer until use. For
the DTG RBS binding assay, 100 μg TMEM97 KO or
TMEM97/PGRMC1 double KO HeLa cell membrane
homogenates and non-radioactive compounds with
concentrations ranging from 1 nM to 10 μM were
incubated with 45 nM [3H]DTG in 50 mM Tris–HCl,
pH 8.0, and 0.1% BSA for 60 min at 37 °C. 500 nM
(+)-pentazocine was added to mask the sigma-1
receptor binding site. The non-speciﬁc binding was
determined in the presence of 60 μM cold DTG.
After incubation, the bound ligands were ﬁltrated with a
M-24 Brandel ﬁltration system (Brandel, Gaithersburg,
MD, USA), collected on glass ﬁber papers (Whatman
grade 934-AH, GE Healthcare Bio-Sciences, Pittsburgh,
PA), and counted with a MicroBeta2 Microplate counter
2450 (Perkin Elmer, Boston, MA). Inhibition constant (Ki)
values of tested compounds were determined by using the
Cheng and Prussoff equation34:
Ki ¼ IC501þ Lt=Kd
where Kd values of [
3H](+)-pentazocine on guinea
pig brain membrane homogenates, [3H]DTG on rat
liver membrane homogenates, [3H]DTG on TMEM97
KO or TMEM97/PGRMC1 double KO HeLa cell
membrane homogenates were 1.5, 20.7 nM (Fig. S1),
302, and 402.6 nM16, respectively, and Lt is the con-
centration of radioligand used in each assay. Ki values
were reported as mean ± SD from at least three inde-
pendent experiments.
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Internalization of SW120
HeLa cells were plated on 35-mm-diameter glass-
bottom dishes at 2 × 105 cells per dish and incubated for
24 h. Prior to imaging, media was removed and fresh
media containing 100 nM SW120 was added to the
dishes. SW120 uptake in the live cells at room tempera-
ture was imaged using an inverted confocal microscope
(Leica STED 3× super-resolution microscope). Images
were acquired at 25 s intervals using a ×10 objective lens
(using an excitation wavelength of 488 nm, and a 505 to
540 nm bandpass ﬁlter). Five optical slices at 2-μm
intervals were scanned using the Z-stack function of the
Leica imaging software. The brightest optical slice out of
the ﬁve Z-stack optical slices was chosen for ﬂuorescent
intensity analysis. Twenty cells were analyzed in each dish
using Fiji, an open-source platform based on ImageJ35.
The ﬂuorescent intensity was calculated as an average of
60 cells from three independent experiments (mean ±
SEM).
Statistical analysis
The results are expressed as the mean ± SD (standard
deviation) or mean ± SEM (standard error) from at least
three independent experiments performed in duplicate or
triplicate. Differences among groups were analyzed by
one-way or two-way ANOVA with a Dunnett’s multiple
comparisons test using GraphPad Prism version 6
(GraphPad Software, Inc. La Jolla, CA). The signiﬁcance
level is 0.05.
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